|
Post by straightly on Sept 30, 2016 10:47:41 GMT -5
I believe in Afrezza and believe in risk mitigation. By that I mean trials, errors, and improvements. I hope MNKD is trying many ways.
|
|
|
Post by gonetotown on Sept 30, 2016 10:48:09 GMT -5
under the heading too little too late. consider; what if the designation, ultra rapid is given afrezza. ? Some of the meta analysis post 2016 are calling afrezza ultra rapid mealtime insulin. The designation is already being used. Peppy, if the Ultra rapid designation comes soon, take me through the sequence of events which you believe would need to take place and how they would impact Afrezza and Mannkind. Also please comment how long the sequence of events would take. Ultra means a new category but for the payors who have exclusive deals for a RAA, are they in the short term going to push back on their vendors? From another perspective, how long until they MNKD reps can pitch a superior clinical value proposition to physicians and other healthcare professionals? Lastly, what kind of DTC could MNKD use to tell patients the clinical benefits of Ultra Rapid acting. Not trying to be a spoil sport, but without a significant infusion of cash, time is no longer our friend. Ultra rapid designation would be a powerful tool but it would be some time until it could be monitized, No? I don't quite understand why so many find an "ultra-rapid" designation particularly significant. Insurance coverage seems so much more important and I don't get the impression insurers care one way or another about rapidity; they want proof of better A1cs.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 10:48:20 GMT -5
Halloween coming and then it's thanksgiving and then it's Christmas.
|
|
|
Post by matt on Sept 30, 2016 10:49:25 GMT -5
The value of the patents, is large. ? The value of any patent, by itself, is zero. If the inventor has a highly successful new product, a patent protects the market from competition for the life of the patent, and in that case the patent has great economic value. If the new product is a failure, the patent is worthless because it protects a commercial market that does not exist. Ultimately, the value of the product determines the value of the patent and not the other way around.
|
|
|
Post by peppy on Sept 30, 2016 10:55:13 GMT -5
I hear you money. outsulin, the character, could become ultra rapid? run> Commenting on how long the sequence of events would take? No clue, however, the literature posted, manmade has been posting a fair share, the writer, designating afrezza as ultra rapid already. Payors, that is Mike C wheelhouse. Regarding payors and pitch. Not every physician is sweeddee dad north Dakota follow the guidelines, see insured and medicare and run an office physician. Some physicians know what is going on and for the elite, services seem to be available. What kind of DTC could mnkd use to tell patients the clinical benefits? Afrezza technosphere insulin. Ultra rapid acting non invasive mealtime insulin. Afrezza peaks in 12 to 15 minutes and returns to baseline in three hours. Ask your physician if Afrezza technosphere insulin is right for you. screencast.com/t/7273Jsj3bZscreencast.com/t/2gNn5UWKXA
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 10:59:41 GMT -5
The value of the patents, is large. ? The value of any patent, by itself, is zero. If the inventor has a highly successful new product, a patent protects the market from competition for the life of the patent, and in that case the patent has great economic value. If the new product is a failure, the patent is worthless because it protects a commercial market that does not exist. Ultimately, the value of the product determines the value of the patent and not the other way around. For the life of me I cannot understand why some other entrepreneurs have not teamed up with MNKD to take older Rx products and reinvigorate them with the Technosphere delivery platform. Any deal could have the partner pay a few bucks to use the Danbury facility for development and I cannot believe the facility is running at capacity for development purposes and if need be, development partner could foot the bill for a couple of additional engineers. A fresh patent along with a new and novel delivery system and a few drugs generating $350mm - $600mm in potential annual revenue with the novel Technosphere delivery system alone would have created nice value for MNKD shareholders. How Fkucking hard is this to do, seriously. Even cash strapped, just lower the price or royalty to a few BPs to keep the lights on. Its also becoming readily apparent that Al was very good to a lot of execs and board members some of which appear to be little more than leaches readily accepting cash and options. Proboards Matt - what is the smallest # of directors MNKD can have and how many have to be outside of the company.
|
|
|
Post by peppy on Sept 30, 2016 11:09:08 GMT -5
The value of the patents, is large. ? The value of any patent, by itself, is zero. If the inventor has a highly successful new product, a patent protects the market from competition for the life of the patent, and in that case the patent has great economic value. If the new product is a failure, the patent is worthless because it protects a commercial market that does not exist. Ultimately, the value of the product determines the value of the patent and not the other way around. MNKD holds many patents. It is conjecture the patents are worthless. Why do you see it that way Matt?
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 30, 2016 11:14:19 GMT -5
I hear what you are saying Peppy and agree. I have lots of time in this space and know what Afrezza brings to the table. Its a matter of what MNKD can say and when vs cash on hand. Getting 1,000 endos on board gives enough distribution, i.e. places for patients to get an Rx to generate enough revenue to keep lights on. Other side of trade is how to get patients walking in and asking doc for it and of course, the payors. Seems like we might be on the cusp but without cash to extend the runway...
|
|
|
Post by gonetotown on Sept 30, 2016 11:17:10 GMT -5
The value of any patent, by itself, is zero. If the inventor has a highly successful new product, a patent protects the market from competition for the life of the patent, and in that case the patent has great economic value. If the new product is a failure, the patent is worthless because it protects a commercial market that does not exist. Ultimately, the value of the product determines the value of the patent and not the other way around. MNKD holds many patents. It is conjecture the patents are worthless. Why do you see it that way Matt?
Has anyone has ever paid or offered serious money for any of the patents? Patents that no one is willing to pay up for aren't very helpful financially.
|
|
|
Post by slugworth008 on Sept 30, 2016 11:24:25 GMT -5
Scripts down week ending 9/23 can't wait to hear the plethora of excuses. Most diabetic nimrods were on vacation last week.
|
|
|
Post by parrerob on Sept 30, 2016 12:08:24 GMT -5
All hopes are not lost, but risk increased. When the doc campaign comes, it's do or die with a short runway. Maybe not, but everytime I look at MNKD the phrase, "Lasciate ogne speranza, voi ch'intrate," seems to flash across the screen. Just to add this sentence is posted at the entrance of the Hell (Dante Alighieri). But, in the same book (Divina Commedia) after a long run through the Hell then there was the purgatory and finally the Paradise.... Hope the road will be the same here.....
|
|
|
Post by liane on Sept 30, 2016 12:21:33 GMT -5
"Lasciate ogne speranza, voi ch'intrate," Used to have that posted over the chemistry lab in high school.
|
|
|
Post by dreamboatcruise on Sept 30, 2016 15:15:39 GMT -5
Peppy, if the Ultra rapid designation comes soon, take me through the sequence of events which you believe would need to take place and how they would impact Afrezza and Mannkind. Also please comment how long the sequence of events would take. Ultra means a new category but for the payors who have exclusive deals for a RAA, are they in the short term going to push back on their vendors? From another perspective, how long until they MNKD reps can pitch a superior clinical value proposition to physicians and other healthcare professionals? Lastly, what kind of DTC could MNKD use to tell patients the clinical benefits of Ultra Rapid acting. Not trying to be a spoil sport, but without a significant infusion of cash, time is no longer our friend. Ultra rapid designation would be a powerful tool but it would be some time until it could be monitized, No? I don't quite understand why so many find an "ultra-rapid" designation particularly significant. Insurance coverage seems so much more important and I don't get the impression insurers care one way or another about rapidity; they want proof of better A1cs. Or... they want cheaper drugs for higher profits but might be forced into giving better treatment to Afrezza if there was clinical superiority evidence which they could not ignore.
|
|
|
Post by matt on Sept 30, 2016 15:56:55 GMT -5
I assume you are addressing this question to me. The answer depends on "Why do you want to know?"
If you are asking the question as a matter of Delaware law, the answer is 1 director and that person does not need to be independent.
The SEC does not regulate corporations, only sale of securities, so they have no say in the matter.
If you are asking assuming that the company wants to remain in compliance with NASDAQ rules, the answer is a bit more complicated. Under NASDAQ rules more than half of all directors must be independent directors, and NASDAQ also requires there be an Audit Committee of at least three members, all of whom must be outside directors, and an Executive Compensation Committee of at least two members, all or whom must be outside directors. All director nominations must be made by the independent directors.
At a minimum, NASDAQ will require three independent directors to constitute the Audit Committee, and those same directors can do double duty as the Compensation Committee. NASDAQ does not require any non-independent directors, so three in total is enough to meet the bare requirement. However, most companies will also have a Corporate Governance and Nominating Committee and the committees do most of the work required by a board. Companies try to avoid having directors on multiple committees, and never in the case where they already serve as a committee chairman. Some companies have Audit Committee meeting every quarter and alternate the Executive Compensation and Corporate Governance Committee meeting every other quarter to spread out the work.
If you want a properly functioning and active board, you need 5-6 board members of which no more than 1 is an inside director. Does that answer your question?
|
|
|
Post by matt on Sept 30, 2016 15:59:36 GMT -5
Maybe not, but everytime I look at MNKD the phrase, "Lasciate ogne speranza, voi ch'intrate," seems to flash across the screen. Which circle have you reached?
|
|